- Target disease: Filarial diseases
- Main partners (since start date): Bayer HealthCare, Germany.
- Start date: March 2013
- Funding (since start date): Bill & Melinda Gates Foundation, USA; USAID, USA; Federal Ministry of Education and Research (BMBF) through KfW and part of the EDCTP2 programme supported by the European Union, Germany.
Emodepside is a semi-synthetic product (originated by Astellas and out-licensed to Bayer for animal and human use); its precursor is synthesized by a fungus living in the leaves of Camellia japonica. It is a potent antihelminthic drug used in combination with praziquantel (as Profender®) and in combination with toltrazuril (as Procox®) for the treatment of parasitic worms in cats and dogs. DNDi and Bayer Pharma AG are jointly developing emodepside for the treatment of onchocerciasis patients. DNDi will be responsible for the pre-clinical and clinical development of emodepside and Bayer for the pharmaceutical development, manufacturing, registration, and supply of the drug at the lowest sustainable price.
The Single Ascending Dose Study was completed in 2017 and the Multiple Ascending Dose Study should be completed in 2018.
Last update: March 2018